Analyst consensus rating
Lantern Pharma Analyst Rating: none
LTRN is rated none by 2 analysts with a $17.50 target. As of 2026-09-02.
Direct answer
Lantern Pharma's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.50.
Forecast evidence checked September 2, 2026.
Get free Lantern Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.08
- Average price target
- $17.50
- High price target
- $25.00
- Low price target
- $10.00
- Low target gap
- +380.8%
- Target upside
- +741.3%
- High target gap
- +1,101.9%
- Target range width
- 721.2%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lantern Pharma?
Lantern Pharma has a verified none consensus. The same dataset has an average price target of $17.50.
How far are Lantern Pharma's low and high targets from the recorded price?
The low target implies +380.8%, while the high target implies +1,101.9%.
How many analysts are included in Lantern Pharma's consensus?
The verified consensus includes 2 analysts.
How is Lantern Pharma's target upside or downside calculated?
The average target of $17.50 is divided by the recorded price of $2.08, then one is subtracted to produce +741.3%. This does not guarantee a future return.
When was Lantern Pharma's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.